Details

Autor(en) / Beteiligte

• Morales, Daniel R., MBChB
• Lipworth, Brian J., MD
• Guthrie, Bruce, PhD
• Jackson, Cathy, MD
• Donnan, Peter T., PhD
• Santiago, Virginia H., MBBM

Titel

Safety risks for patients with aspirin-exacerbated respiratory disease after acute exposure to selective nonsteroidal anti-inflammatory drugs and COX-2 inhibitors: Meta-analysis of controlled clinical trials

Ist Teil von

• Journal of allergy and clinical immunology, 2014-07, Vol.134 (1), p.40-45.e10

Ort / Verlag

New York, NY: Elsevier Inc

Erscheinungsjahr

2014

Quelle

MEDLINE

Beschreibungen/Notizen

• Background Nonsteroidal anti-inflammatory drugs (NSAIDs) cause bronchospasm in susceptible patients with asthma, often termed aspirin-exacerbated respiratory disease (AERD), with the risk being greatest after acute exposure. Selective NSAIDs that preferentially inhibit COX-2 might be safer. Objective We sought to systematically evaluate changes in symptoms and pulmonary function after acute selective NSAID or COX-2 inhibitor exposure in patients with the AERD phenotype. Methods A systematic review of databases was performed to identify all blinded, placebo-controlled clinical trials evaluating acute selective NSAID or COX-2 inhibitor exposure in patients with AERD. Effect estimates for changes in respiratory function and symptoms were pooled by using fixed-effects meta-analysis, with heterogeneity investigated. Results No significant difference in respiratory symptoms (risk difference, −0.01; 95% CI, −0.03 to 0.01; P  = .57), decrease in FEV1 of 20% or greater (RD, 0.00; 95% CI, −0.02 to 0.02; P  = .77), or nasal symptoms (RD, −0.01; 95% CI, −0.04 to 0.02; P  = .42) occurred with COX-2 inhibitors (eg, celecoxib). Selective NSAID exposure caused respiratory symptoms in approximately 1 in 13 patients with AERD (RD, 0.08; 95% CI, 0.02 to 0.14; P  = .01). No significant differences were found according to leukotriene antagonist exposure or whether NSAIDs were randomly allocated. Conclusion According to clinical trial evidence in patients with stable mild-to-moderate asthma with AERD, acute exposure to COX-2 inhibitors is safe, and selective NSAIDs exhibit a small risk. Thus COX-2 inhibitors could be used in patients with AERD or in patients with general asthma unwilling to risk nonselective NSAID exposure when oral challenge tests are unavailable.